We found deregulated proteins in resistant cells that may be potential biomarkers of response to therapy and may be involved in therapy resistance, useful to predict survival and response to trastuzumab therapy in HER2-positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.